Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy

Abstract:    Recent approval of Epidiolex
(pharmaceutical cannabidiol/CBD) for the treatment of Lennox Gastaut syndrome (LGS) and Dravet syndrome highlights a therapeutic efficacy of CBD in the treatment of epilepsy. […]

July 27, 2021

Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist

Background and purpose: Cannabis is the source of at least seventy phytocannabinoids. The pharmacology of most of these has been little investigated, three notable exceptions being D9 -tetrahydrocannabinol, cannabidiol and […]

July 13, 2021

Phytocannabinoids promote viability and functional adipogenesis of bonemarrow-derived mesenchymal stem cells through different molecular targets

Abstract: The cellular microenvironment plays a critical role in the maintenance of bone marrow-derived mesenchymal stem cells (BM-MSCs) and their subsequent cell lineage differentiation. Recent studies suggested that individuals with […]

In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid

Abstract: Inflammation and oxidative stress play main roles in neurodegeneration. Interestingly, different natural compounds may be able to exert neuroprotective actions against inflammation and oxidative stress, protecting from neuronal cell […]

The Pharmacological Case for Cannabigerol

ABSTRACT   Medical cannabis and individual cannabinoids, such as D9- tetrahydrocannabinol (D9-THC) and cannabidiol (CBD), are receiving growing attention in both the media and the scientific literature. The Cannabis plant, […]

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabisderived non-psychotropic cannabinoid

Cannabigerol (CBG) is a safe non-psychotropic Cannabis-derived cannabinoid (CB), which interacts with specific targets involved in carcinogenesis. Specifically, CBG potently blocks transient receptor potential (TRP) M8 (TRPM8), activates TRPA1, TRPV1 […]

A cannabigerol-rich Cannabis sativa extract, devoid of ∆-9 tetrahydrocannabinol, elicits hyperphagia in rats

Abstract   Objective: Non-psychoactive phytocannabinoids (pCBs) from Cannabis sativa may represent novel therapeutic options for cachexia due to their pleiotropic pharmacological activities, including appetite stimulation. We have recently shown that […]

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease

Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized by progressive loss of cognition. Over 35 million individuals currently have AD worldwide. Unfortunately, current therapies are limited to very […]

July 8, 2021

Neurological Aspects of Medical Use of Cannabidiol

Abstract:   Background: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential […]

Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case SeriesCannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series

Abstract   Objectives: Cannabidiol (CBD) is a non-psychotomimetic cannabinoid compound that is found in plants of the genus Cannabis. Preclinical research has suggested that CBD may have a beneficial effect […]

June 14, 2021